Stratos Wealth Partners LTD. Reduces Stock Holdings in Medtronic PLC $MDT

Stratos Wealth Partners LTD. cut its stake in shares of Medtronic PLC (NYSE:MDT) by 9.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 74,371 shares of the medical technology company’s stock after selling 7,442 shares during the period. Stratos Wealth Partners LTD.’s holdings in Medtronic were worth $7,144,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of MDT. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic during the second quarter valued at approximately $27,000. Corundum Trust Company INC purchased a new position in shares of Medtronic in the third quarter valued at $27,000. Lodestone Wealth Management LLC acquired a new stake in Medtronic during the 4th quarter valued at $27,000. Valley Wealth Managers Inc. acquired a new stake in Medtronic during the 3rd quarter valued at $29,000. Finally, Board of the Pension Protection Fund purchased a new stake in Medtronic during the 4th quarter worth $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $86.61 on Friday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $111.19 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 2.24 and a beta of 0.75. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The business has a 50 day simple moving average of $94.47 and a 200-day simple moving average of $96.24.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the business posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.26% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on MDT. Wells Fargo & Company assumed coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price objective on the stock. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Barclays boosted their price target on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $120.00 price target on shares of Medtronic in a report on Thursday, March 26th. Finally, Truist Financial lowered their price objective on Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $109.85.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).